PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26342829-10 2015 Lower concentrations of thrombin resulted in equivalent neuroprotection as the antifibrinolytic, aprotinin, and the direct thrombin inhibitor, argatroban. argatroban 143-153 coagulation factor II Rattus norvegicus 24-32 31157200-7 2019 The dose-dependent thrombin clotting time (TCT) delay caused by Supra-TBA15/29-GO was >10 times longer than that of common anticoagulant drugs including heparin, argatroban, hirudin, and warfarin. argatroban 165-175 coagulation factor II Rattus norvegicus 19-27 28695302-9 2017 We used argatroban, a direct thrombin inhibitor for targeting PAR. argatroban 8-18 coagulation factor II Rattus norvegicus 29-37 28695302-18 2017 Reduced expression of PAR1 and PAR4 in the argatroban-treated group indicates a response towards inhibition of thrombin. argatroban 43-53 coagulation factor II Rattus norvegicus 111-119 29971544-6 2019 In this study, we have investigated the effects of argatroban; a direct thrombin inhibitor against DCM in streptozotocin-induced type-1 diabetes. argatroban 51-61 coagulation factor II Rattus norvegicus 72-80 22649241-5 2012 Intravenous infusion of argatroban, a direct thrombin inhibitor, alleviated neurovascular injury. argatroban 24-34 coagulation factor II Rattus norvegicus 45-53 24473182-0 2014 Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. argatroban 26-36 coagulation factor II Rattus norvegicus 7-15 24473182-1 2014 BACKGROUND AND PURPOSE: We showed previously robust neuroprotection with the thrombin inhibitor argatroban and now sought additional support for its neuroprotective potential. argatroban 96-106 coagulation factor II Rattus norvegicus 77-85 20806115-2 2010 We investigated the effects of the direct thrombin inhibitor, argatroban (ARG), on the sepsis-induced impairment of the intestinal microcirculation (capillary perfusion, leukocyte adhesion) and the vascular contractility in rats. argatroban 62-72 coagulation factor II Rattus norvegicus 42-50 21803126-8 2011 Our results showed that the levels of PAR-1 protein or PAR-1 mRNA in ICH and TM groups were up-regulated compared to that observed for the sham group; while the levels observed in ICH+Arg group and TM+Arg group were significantly lower than that observed for the ICH group and TM group (P<0.01 or P<0.05). argatroban 184-187 coagulation factor II Rattus norvegicus 77-79 21803126-8 2011 Our results showed that the levels of PAR-1 protein or PAR-1 mRNA in ICH and TM groups were up-regulated compared to that observed for the sham group; while the levels observed in ICH+Arg group and TM+Arg group were significantly lower than that observed for the ICH group and TM group (P<0.01 or P<0.05). argatroban 201-204 coagulation factor II Rattus norvegicus 77-79 21803126-9 2011 The intraperitoneal administration argatroban also significantly reduced edema in ICH or TM group (P<0.05). argatroban 35-45 coagulation factor II Rattus norvegicus 89-91 21803126-10 2011 Our observations suggested that the production of thrombin following ICH play a key role in the up-regulation of PAR-1 and anti-PAR-1 by systemic administration of argatroban, and may be a potential strategy for ICH therapy. argatroban 164-174 coagulation factor II Rattus norvegicus 50-58 20806115-2 2010 We investigated the effects of the direct thrombin inhibitor, argatroban (ARG), on the sepsis-induced impairment of the intestinal microcirculation (capillary perfusion, leukocyte adhesion) and the vascular contractility in rats. argatroban 74-77 coagulation factor II Rattus norvegicus 42-50 19388346-1 2008 BACKGROUND: Our previous studies have demonstrated that argatroban, a specific thrombin inhibitor, reduces brain edema and neurological deficits in rat glioma models. argatroban 56-66 coagulation factor II Rattus norvegicus 79-87 20705928-10 2010 Vascular disruption was blocked by intravenous infusion of the direct thrombin inhibitor argatroban (1.69 mg/kg, P<0.05). argatroban 89-99 coagulation factor II Rattus norvegicus 70-78 19228846-0 2009 Thrombin inhibition by argatroban ameliorates early brain injury and improves neurological outcomes after experimental subarachnoid hemorrhage in rats. argatroban 23-33 coagulation factor II Rattus norvegicus 0-8 19228846-3 2009 Low-dose (0.3 mg/h) and high-dose (0.9 mg/h) argatroban, a direct thrombin inhibitor, were evaluated for effects on brain edema, blood-brain barrier (BBB) disruption, apoptotic cell death, inflammatory marker, and neurological outcomes after SAH. argatroban 45-55 coagulation factor II Rattus norvegicus 66-74 19228846-5 2009 CONCLUSIONS: Thrombin inhibition by argatroban improves neurological outcomes and provides neuroprotection against acute events after SAH such as BBB disruption, brain edema, and cell death. argatroban 36-46 coagulation factor II Rattus norvegicus 13-21 18622025-11 2008 We also examined the inhibitory effect of argatroban, a synthetic thrombin inhibitor, and prednisolone in the production of MCP-1 and MIP-2 stimulated by thrombin. argatroban 42-52 coagulation factor II Rattus norvegicus 154-162 18622025-14 2008 The stimulating effect of thrombin on the production of MCP-1 and MIP-2 was inhibited by the addition of argatroban or prednisolone. argatroban 105-115 coagulation factor II Rattus norvegicus 26-34 19388346-11 2008 In vitro, thrombin increased DNA synthesis in C6 glioma cells, and this effect was blocked by argatroban. argatroban 94-104 coagulation factor II Rattus norvegicus 10-18 17498698-5 2007 Intracerebroventricular injection of argatroban or cycloheximide, both of which prevent thrombin cytotoxicity in vitro, exhibited a significant neuroprotective effect against ICH-induced injury. argatroban 37-47 coagulation factor II Rattus norvegicus 88-96 16463890-1 2005 Our previous studies showed that intracerebral infusion of argatroban, a specific thrombin inhibitor, reduces brain edema and neurological deficits in a C6 glioma model. argatroban 59-69 coagulation factor II Rattus norvegicus 82-90 15975137-1 2005 BACKGROUND: In a previous study we found that intracerebral infusion of argatroban, a specific thrombin inhibitor, reduces brain edema and neurologic deficits in a C6 glioma model. argatroban 72-82 coagulation factor II Rattus norvegicus 95-103 15980248-3 2005 This study was designed to evaluate quantitatively the inhibitory effects of argatroban, a direct thrombin inhibitor, on leukocyte-endothelial cell interactions and vascular permeability after scatter laser photocoagulation. argatroban 77-87 coagulation factor II Rattus norvegicus 98-106 16463890-11 2005 These results suggest that thrombin plays a key role in glioma growth and thrombin inhibition with argatroban may be a novel treatment for gliomas. argatroban 99-109 coagulation factor II Rattus norvegicus 74-82 15665510-1 2005 This study investigated the effects of argatroban, a thrombin inhibitor, on brain edema and inflammation in a rat intracerebral hemorrhage (ICH) model. argatroban 39-49 coagulation factor II Rattus norvegicus 53-61 12869718-1 2003 BACKGROUND AND PURPOSE: Argatroban, a direct thrombin inhibitor, has been shown to reduce neural injury after transient cerebral ischemia. argatroban 24-34 coagulation factor II Rattus norvegicus 45-53 14753434-1 2003 The aim of this study is to determine whether a selective thrombin inhibitor, Argatroban, would prevent neuronal cell death and whether extra-mild hypothermia (35 degrees C) would enhance the neuroprotective effect of a selective thrombin inhibitor following transient focal ischemia in rats. argatroban 78-88 coagulation factor II Rattus norvegicus 58-66 14753486-4 2003 This study examines whether a thrombin inhibitor, argatroban, can reduce edema formation following intracerebral infusion of 100 microl of blood in the rat, the therapeutic time window for argatroban, and whether argatroban promotes rebleeding. argatroban 50-60 coagulation factor II Rattus norvegicus 30-38 14753495-5 2003 Anti-thrombin treatment with argatroban reduced brain edema, tumor growth, and tumor-related neurological deficits. argatroban 29-39 coagulation factor II Rattus norvegicus 5-13 14753434-9 2003 These results demonstrate that extra-mild hypothermia (35 degrees C) enhances neuroprotective effects of a selective thrombin inhibitor, argatroban, suggesting that this combined therapy may be a new therapeutic strategy for the treatment of acute stroke. argatroban 137-147 coagulation factor II Rattus norvegicus 117-125 10706937-7 2000 Argatroban, a selective synthetic thrombin inhibitor, significantly prolonged the occlusion time. argatroban 0-10 coagulation factor II Rattus norvegicus 34-42 12468805-5 2002 METHODS: This study examines (1) whether argatroban, an inhibitor of both free and fibrin-bound thrombin, can reduce edema formation after intracerebral infusion of 100 micro L of blood in the rat; (2) the therapeutic time window for argatroban; and (3) whether argatroban promotes rebleeding in a model in which ICH was induced by intracerebral injection of collagenase. argatroban 41-51 coagulation factor II Rattus norvegicus 96-104 10959702-5 2000 The antithrombotic activity of argatroban was accompanied by increases in the thrombin and ecarin clotting times but not the aPTT, whereas heparin increased the thrombin time and aPTT but not the ecarin clotting times. argatroban 31-41 coagulation factor II Rattus norvegicus 78-86 8797131-0 1996 Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. argatroban 75-85 coagulation factor II Rattus norvegicus 43-51 9870892-1 1998 Argatroban, a synthetic thrombin inhibitor, and ticlopidine, an anti-platelet agent, are major antithrombotic agents. argatroban 0-10 coagulation factor II Rattus norvegicus 24-32 8768731-0 1996 Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. argatroban 33-43 coagulation factor II Rattus norvegicus 13-21 9175233-2 1997 The aim of the present study was to assess the use of a synthetic, low molecular weight thrombin inhibitor, argatroban in association with a well defined thrombolytic agent in a reproducible animal model of thrombolysis in vivo. argatroban 108-118 coagulation factor II Rattus norvegicus 88-96 9469624-0 1997 Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis. argatroban 10-20 coagulation factor II Rattus norvegicus 34-42 7630043-8 1995 The effect of argatroban is attributable to inhibition of thrombin-induced platelet activation and fibrin generation. argatroban 14-24 coagulation factor II Rattus norvegicus 58-66 8569051-2 1995 We determined whether microthrombi contribute to the spreading of ischemic lesions following thrombotic middle cerebral artery (MCA) occlusion and also determined whether argatroban, a selective thrombin inhibitor, reduces the formation of the microthrombi and the area of the ischemic lesions. argatroban 171-181 coagulation factor II Rattus norvegicus 195-203 7559923-8 1995 Thus, argatroban, which antagonizes thrombin, can improve microvascular circulation in congestive tissue and consequently help the flap survive. argatroban 6-16 coagulation factor II Rattus norvegicus 36-44 8944418-12 1996 The selective thrombin inhibitor argatroban, on the other hand, led to shortened lysis time. argatroban 33-43 coagulation factor II Rattus norvegicus 14-22 8225173-11 1993 Platelet aggregation induced by KDH-8 tumor cells was inhibited by ADP inhibitor (apyrase, CP/CPK) and thrombin inhibitor (heparin, MD-805); KDH-8 tumor cells induced platelet aggregation by two different mechanisms: ADP-mediated aggregation and thrombin-mediated aggregation. argatroban 132-138 coagulation factor II Rattus norvegicus 103-111 7889274-2 1994 The antithrombotic action of argatroban, a synthetic thrombin inhibitor, was studied in three models of thrombosis in the rat, and in the tail transection bleeding time test. argatroban 29-39 coagulation factor II Rattus norvegicus 53-61 7889274-19 1994 Hoever, the antithrombotic effects of argatroban were accompanied by only moderate changes in the coagulation parameters (thrombin time and activated partial thromboplastin time, APTT), whereas, even at a subthreshold dose of heparin (12.5 pg kg-1 min-1), both the thrombin time and the APTT were greater than 150 s.5. argatroban 38-48 coagulation factor II Rattus norvegicus 122-130 7889274-19 1994 Hoever, the antithrombotic effects of argatroban were accompanied by only moderate changes in the coagulation parameters (thrombin time and activated partial thromboplastin time, APTT), whereas, even at a subthreshold dose of heparin (12.5 pg kg-1 min-1), both the thrombin time and the APTT were greater than 150 s.5. argatroban 38-48 coagulation factor II Rattus norvegicus 265-273 7843647-1 1994 The preventive effect of argatroban, a synthetic thrombin inhibitor, on cerebral infarction was evaluated with ellagic acid (EA)-induced cerebral thromboembolism in rats. argatroban 25-35 coagulation factor II Rattus norvegicus 49-57 8331553-9 1993 The effect of thrombin on [Ca++]i was abolished by the thrombin inhibitor MD-805, whereas the responses to TRAP were unaffected. argatroban 74-80 coagulation factor II Rattus norvegicus 14-22 8331553-9 1993 The effect of thrombin on [Ca++]i was abolished by the thrombin inhibitor MD-805, whereas the responses to TRAP were unaffected. argatroban 74-80 coagulation factor II Rattus norvegicus 55-63 8387299-4 1993 The active site inhibitor, MD805 (argatroban), and the anion-binding exosite inhibitor, BMS 180,742, reduced the IP response to alpha-thrombin in a concentration-dependent manner. argatroban 27-32 coagulation factor II Rattus norvegicus 134-142 8387299-4 1993 The active site inhibitor, MD805 (argatroban), and the anion-binding exosite inhibitor, BMS 180,742, reduced the IP response to alpha-thrombin in a concentration-dependent manner. argatroban 34-44 coagulation factor II Rattus norvegicus 134-142 1957278-9 1991 A synthetic thrombin inhibitor, argatroban, also showed a potent antithrombotic effect, but a thrombolytic agent, urokinase, was less effective. argatroban 32-42 coagulation factor II Rattus norvegicus 12-20 31175488-8 2019 Inhibition of thrombin formation with argatroban abolished the increase in free hemoglobin concentration, schistocyte formation, and disseminated intravascular coagulation in LPS-treated animals. argatroban 38-48 coagulation factor II Rattus norvegicus 14-22 31175488-12 2019 The thrombin inhibitor argatroban but not the platelet inhibitor eptifibatide abolished hemolysis and schistocyte formation. argatroban 23-33 coagulation factor II Rattus norvegicus 4-12 31666085-11 2019 Like AB, TMalpha at 10 mg/kg prevented the oxaliplatin-induced allodynia in mice as well as rats, an effect abolished by argatroban at 10 mg/kg, a thrombin inhibitor. argatroban 121-131 coagulation factor II Rattus norvegicus 147-155